CASE Op-Ed in RealClear Markets: Gary Gensler’s Blundering SEC Mirrors Biden’s Incompetence
Touting historically low approval ratings rivaling that of paper cuts and hay fever, one might think Joe Biden and his handlers...
CASE Op-Ed in The Daily Caller: Gary Gensler’s SEC Is Killing Innovators While Sheltering Cronies
December 8, 2023 As new and revolutionary technologies have improved the economy throughout our nation’s history, Washington has often...
CASE Op-Ed – InsideSources: Stone-Age Bureaucracy Is Bungling America’s Cryptocurrency Future
Gerard Scimeca – Chairman, CASE July 5, 2021 Imagine trying to make a purchase online from a familiar website,...
CASE Op-ed – Morning Consult: The Price Will Be Steep if the United States Lets Crypto Innovation Slip Through Its Fingers
Gerard Scimeca – Chairman, CASE November 18th, 2020 There is no denying that all of us are now witnessing a...
CASE Op-ed – Morning Consult: Washington Can’t Pass the Buck on Cryptocurrency Framework
Gerard Scimeca – Chairman, CASE January 14, 2020 Before he became the world’s richest man, Jeff Bezos was sailing in...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/